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Abstract 
Background: After spinal cord (SC)‑injury, a non‑modulated immune response contributes to the damage of neural 
tissue. Protective autoimmunity (PA) is a T cell mediated, neuroprotective response induced after SC‑injury. Immuniza‑
tion with neural‑derived peptides (INDP), such as A91, has shown to promote—in vitro—the production of neuro‑
trophic factors. However, the production of these molecules has not been studied at the site of injury.
Results: In order to evaluate these issues, we performed four experiments in adult female Sprague–Dawley rats. In 
the first one, brain derived neurotrophic factor (BDNF) and neurotrophin‑3 (NT‑3) concentrations were evaluated at 
the site of lesion 21 days after SC‑injury. BDNF and NT‑3 were significantly increased in INDP‑treated animals. In the 
second experiment, proliferation of anti‑A91 T cells was assessed at chronic stages of injury. In this case, we found a 
significant proliferation of these cells in animals subjected to SC‑injury + INDP. In the third experiment, we explored 
the amount of BDNF and NT3 at the site of injury in the chronic phase of rats subjected to either SC‑contusion (SCC; 
moderate or severe) or SC‑transection (SCT; complete or incomplete). The animals were treated with INDP immedi‑
ately after injury. Rats subjected to moderate contusion or incomplete SCT showed significantly higher levels of BDNF 
and NT‑3 as compared to PBS‑immunized ones. In rats with severe SCC and complete SCT, BDNF and NT‑3 concentra‑
tions were barely detected. Finally, in the fourth experiment we assessed motor function recovery in INDP‑treated rats 
with moderate SC‑injury. Rats immunized with A91 showed a significantly higher motor recovery from the first week 
and up to 4 months after SC‑injury.
Conclusions: The results of this study suggest that PA boosted by immunization with A91 after moderate SC‑injury 
can exert its benefits even at chronic stages, as shown by long‑term production of BDNF and NT‑3 and a substantial 
improvement in motor recovery.
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Background
Spinal cord (SC)-injury triggers a cascade of events that 
include an important local inflammatory response at the 
site of injury [1]. Inflammation, although commonly elic-
ited in order to achieve repair of injured tissues, has del-
eterious effects that lead to increased neuronal loss and 
poor functional recovery after SC-injury [2]. Therefore, 
regulation of this phenomenon after injury is of impera-
tive importance in order to limit these destructive effects.
Protective autoimmunity is a physiological T-cell-
dependent, anti-inflammatory and neuroprotective 
immune response to central nervous system (CNS) 
trauma [3, 4]. In fact, studies have shown that autoim-
mune T cells directed against CNS myelin basic protein 
(MBP) promote recovery after contusion of the SC [5].
One way of boosting protective autoimmunity is 
through active immunization with non-encephalitogenic 
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peptides. A91 is a peptide derived from MBP (sequence 
87–99) in which the lysine residue at position 91 has 
been replaced with alanine. Active immunization with 
A91 induces the proliferation of CNS-antigen-spe-
cific T-cells (in this case, anti A91 T-cells). These cells, 
instead of having deleterious inflammatory effects, exert 
protective actions, which promote neuroprotection 
through the reduction of nitric oxide and lipid peroxida-
tion [6, 7].
Several studies from our laboratory have shown that 
immunization with A91, alone or in combination with 
other strategies, improves functional recovery after 
SC-injury [8, 9]. Nevertheless, in animals with severe 
SC-injury, these beneficial effects are not observed 
[9]. Additionally, we have found that active immuniza-
tion with A91 induces a Th2 phenotype expression [9], 
these cells were found capable of releasing significant 
amounts of brain-derived neurotrophic factor (BDNF) 
when activated in  vitro with A91-peptide. This find-
ing could explain, at least in part, the beneficial effects 
on functional recovery after SC-injury observed in rats 
immunized with A91 [9]. In the light of these findings 
we decided now to explore whether A91-peptide immu-
nization is capable of increasing BDNF and/or neurotro-
phin-3 (NT-3) concentrations at the site of injury shortly 




Sample size for each experiment was calculated using 
an alpha of 0.05 and beta of 0.20. All animals were ran-
domized to each experiment and basal statistical analy-
sis of weight and age yielded no statistical significance 
between experimental sets.
Four experiments were performed. In the first one, 
we explored whether A91 immunization is capable of 
inducing BDNF and NT3 at the site of lesion, specifi-
cally shortly after SC-injury. In the second experiment, 
we study if A91 immunization induced a T-cell response 
that could be observed up to the chronic stage of injury 
(4  months). In the third experiment, we investigated 
whether A91 immunization induces a long-term (after 
4 months) production of BDNF and NT-3 at the site of 
injury. In this case, rats were subjected to SC-injury as 
follows: a first group of rats was subjected to a moder-
ate or severe contusion. In a second group, rats were 
subjected either to hemisection or a complete SC-tran-
section. Each experiment (experiments 1–3) was per-
formed by triplicate. Finally, in the fourth experiment the 
motor recovery of animals with moderate SC-injury was 
investigated.
Animals
Adult female Sprague–Dawley rats (13–14  weeks old, 
200–220 g) were supplied by the Animal Breeding Center 
of Proyecto Camina A. C. Efforts were made to minimize 
the number and suffering of animals used for this project.
Spinal cord injury
Rats were anesthetized by intramuscular injection of 
ketamine (80  mg/kg; PISA Laboratories, Mexico City, 
Mexico) and xylazine (12.5  mg/kg; Bayer Laboratories, 
Mexico City, Mexico). After anesthesia induction, a 
laminectomy and exposure of the spinal cord was per-
formed at T9. Rats were subjected to spinal cord contu-
sion (SCC) or spinal cord transection (SCT). For SCC, a 
10-g rod was dropped onto the exposed spinal cord from 
a height of 25 or 50 mm for a moderate or severe contu-
sion, respectively, using the NYU impactor (NYU, New 
York). This device is capable of inflicting a well-calibrated 
contusive injury of the SC [10]. For SCT, the dura mater 
was dissected and separated from the spinal cord with a 
30-gauge needle. Complete transection was performed 
using iridectomy scissors. Accuracy of the injury was 
visually verified by passing a micro-hook through the 
internal contour of the dura. For incomplete transection, 
approximately 50 % of the dorsal spinal cord was trans-
versely cut sliding a straight-edged scalpel blade through 
the spinal cord. After injury, the aponeurotic plane was 
sutured with poliglycolic acid and the skin, with nylon 
thread.
Animal care
Animals were matched for age and weight in each 
experiment and housed in pairs in a light- and temper-
ature-controlled room. To minimize stress, animals were 
handled daily at least once a day 7 days prior to the surgi-
cal procedure.
Sterile bedding and filtered water was replaced daily. 
Bladder emptying was performed by manual expression 
three times a day until automatic voidance was regained. 
During the first day after injury, the animals received a 
course of enrofloxacine (Marvel, Mexico City, Mexico) 
in their drinking water at an approximate dose of 64 mg/
kg/day. All rats were carefully monitored for evidence of 
postsurgical complications. Animals with signs of infec-
tions were excluded from the study.
Antigen (A91 peptide)
A91 peptide was derived from the encephalitogenic 
sequence of myelin basic protein (MBP; amino acids 
87–99). Non-encephalitogenicity was obtained by replac-
ing the lysine residue at position 91 with alanine. The 
modified peptide was purchased form Invitrogen Life 
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Technologies (San Diego CA, USA). Reverse- phase 
HPLC confirmed that the purity of the A91 peptide was 
>95 %.
Active immunization
Rats were immunized subcutaneously at the base of 
the tail with 150 μg of A91 in phosphate buffered saline 
(PBS), emulsified in an equal volume of complete Fre-
und’s adjuvant (CFA) containing 0.5  mg/ml Mycobacte-
rium tuberculosis (Sigma, St. Louis MO). Immunization 
was performed within a 60 min frame after injury.
T cell proliferation
Cells were pooled from excised inguinal lymph nodes 
4  months after SC-injury. The cells were cultured in 
quintuplicate flat-bottomed wells in 0.2  ml of RPMI-
1640 medium (Gibco, New York) supplemented with 
10  % fetal bovine serum (Gibco, New York) on a 96—
well microtiter plate. Cells (2.5 × 105 cells per well) were 
cultured 72  h in antigen-free medium or together with 
A91 (10  μg/ml), ovalbumin (OVA; 10  μg/ml; Sigma), or 
concanavalin-A (ConA; 10  μg/ml; Sigma St. Louis MO) 
at 37 °C in 5 % CO2. After two washes with RPMI-1640, 
cells were labeled with carboxyfluorescein diester anime 
(CFSE) (Molecular Probes). CFSE-labeled cells divide 
and its progeny are endowed with half the number of 
carboxyfluorescein-tagged molecules, thus each cell divi-
sion can be assessed by measuring the corresponding 
decrease in cell fluorescence. 5 μl of CFSE at a final con-
centration of 1  μM were rapidly dispensed into the cell 
suspension insuring a homogeneous labeling. Cells were 
incubated for 24  h at 37  °C. Staining was halted by the 
addition of an equal volume of fetal bovine serum. The 
proliferative response was determined by flow cytometry. 
Cells were also stained with phycoerythrin-labeled anti-
CD4 monoclonal antibodies (BD Pharmigen, San Diego, 
CA); unstained cells were used as controls. Cells stained 
with CFSE and CD4 were analyzed.
For analysis, the area of lymphocytes was selected 
based on the light scattering characteristics (size/granu-
larity) of these cells. Afterwards, the area of CD4+ cells 
was selected and analyzed for CFSE fluorescence. Mean 
fluorescence intensity data was obtained from fluores-
cence histograms to evaluate the fractions of T cells that 
have completed a given number of divisions. Ten thou-
sand events were collected for each sample of a FACS-
CAlibur flow cytometer (BD Bioscence, Mountain View, 
CA) and analyzed using CellQuest Pro software (BD 
Bioscences). The stimulation index (SI) was calculated by 
dividing the mean percentage of proliferation in experi-
mental wells by the mean percentage of proliferation the 
corresponding control wells (cells cultured in antigen-
free medium).
BDNF and NT3 analysis
After lethal pentobarbital injection, SC samples (2.5 cm 
including the site of injury) were rapidly excised. The 
tissue samples were weighed and snap frozen in liq-
uid nitrogen prior to storage at −70 °C. Within 2 weeks 
of freezing, tissue samples were homogenized in ice 
cold homogenization buffer consisting of 100 mM Tris/
Hcl, pH 7, 2 % bovine serum albumin (BSA), 1 M NaCl, 
4 mM EDTA, 2 % Triton X-100, 0.1 % NaN3, and the fol-
lowing protease inhibitors: 5  µg/mL aprotinin, 0.5  µg/
mL antipain, 157  µg/mL benzamidine, 0.1  µg/mL pep-
statin A and 17 µg/mL phenylmethyl-sulphonyl fluoride. 
Homogenates were prepared in approximately 20 vol-
umes of the homogenization buffer to tissue-wet weight. 
The homogenates were centrifuged at 14,000×g for 
30 min. The resulting supernatants were divided into two 
equal samples and used for the BDNF and NT-3 assays. 
The samples were analyzed by triplicate and following 
the instructions of the ChemiKine™ BDNF and NT-3 
Sandwich ELISA Kit (Millipore, USA). Absorbance was 
measured in a microplate spectrophotometer at a 450 nm 
wavelength (MultiSkan, Thermo Scientific, Finland).
Assessment of motor recovery
Behavioral recovery was assessed every week after spi-
nal cord contusion using the Basso, Beattie and Bresna-
han (BBB) open-field test of locomotor ability [11]. Three 
separate blinded observers evaluated all animals and the 
average of the three scores was used.
Statistical analysis
Data was analyzed using the GraphPad Prism 3.0 soft-
ware and presented as mean ± standard deviation (SD). 
The proliferative response was evaluated using the Stu-
dent’s t-test. BDNF and NT-3 levels were analyzed using 
a Mann-Whitey U test. Motor recovery was evaluated 
using a two-way ANOVA for repeated measures. Differ-
ences of p ≤ 0.05 were considered statistically significant.
Results
Production of BDNF and NT‑3 is increased in the site 
of injury after A91‑immunization
In a previous work, we reported that anti-A91 T cells 
from SC injured rats are capable of producing BDNF 
after an in  vitro challenge with A91-peptide [9]. In line 
with this, we investigated now if A91-immunization is 
capable of increasing the levels of BDNF and/or NT-3 at 
the site of injury. For this purpose ten rats were subjected 
to a moderate contusion and immediately immunized 
with a single dose of A91 (n = 5) or PBS (n = 5). Twenty-
one days after SC-injury (time to ensure the activation of 
A91-reactive T-cell in this experimental model) we deter-
mined the levels of BDNF or NT-3 at the site of lesion. 
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As can be seen in Fig.  1, A91-immunization induced a 
significant increase in both BDNF and NT-3 molecules. 
The levels of BDNF were of 0.165 ±  0.01 (mean ±  SD) 
in A91-immunized animals while the ones observed in 
PBS-immunized ones were of 0.076 ±  0.02 (p =  0.002; 
Mann–Whitney U test, Fig.  1a). In the same way, NT-3 
concentrations in rats receiving A91-immunization were 
significantly higher (0.133 ±  0.02) than those presented 
by PBS-immunized animals (0.062  ±  0.01; p  =  0.03, 
Mann–Whitney U test, see Fig. 1b).
Long‑term immune response and production of BDNF 
and NT‑3 in A91‑immunized rats
Based on the fact that SC-injury induces a chronic 
response against neural antigens [12] and considering 
that neural-derived peptides are proficient to induce an 
immune reaction [8] we decided to explore if A91-immu-
nization is capable of inducing a long-term specific T-cell 
response that could maintain or increase the produc-
tion of neurotrophic factors, even in the chronic phase 
of injury. In order to elucidate this issue, in a first step, 
we proceeded to determine the proliferative response 
of anti-A91 T cells in rats subjected to SC-injury. Thus, 
rats were subjected to a moderate contusion and then 
immediately immunized with A91 peptide (n  =  5) or 
only PBS (n  =  5). Proliferation of anti-A91 cells was 
assessed 4  months after SC-injury. Figure  2 shows that 
A91-immunization induced a long-term response. The 
stimulation index observed in A91-immunized rats was 
significantly higher (1.87  ±  0.09, mean  ±  SD) as com-
pared to the one presented by PBS immunized animals 
(0.89 ± 0.05; p = 0.001, Student t test).
In view of the above results, we then explored the lev-
els of BDNF and NT-3 molecules at the site of lesion of 
rats with SC-injury in the chronic stage (4 months after 
SC-injury). In order to attain a more comprehensive 
study, we designed a broad experiment where other dif-
ferent models of SC-injury were included. In this way, 
ten rats were subjected to a moderate (n = 5) or a severe 
(n = 5) contusion. In the same experiment, other ten rats 
were subjected to hemisection (n = 5) or a complete SC-
transection (n =  5). BDNF and NT-3 levels were deter-
mined by ELISA assay and thus were compared among 
all groups. This experiment was performed by triplicate. 
Figures  3 and 4 show that A91 immunization elicited 
the production of BDNF and NT3 in chronic stages of 
injury; however, this effect was not observed in all SC-
injury models. Rats immunized with A91–peptide and 
subjected to moderate contusion (Fig. 3a) or hemisection 
(Fig.  3b) presented higher levels of BDNF (0.12  ±  0.01 
and, 0.11 ± 0.02 respectively, mean ± SD) as compared 
to PBS-immunized ones (0.06  ±  0.01 and 0.05  ±  0.03 
respectively; p = 0.004, Mann–Whitney U test). In con-
trast, the levels of this molecule were barely detected 
in animals with severe contusion (A91: 0.05  ±  0.02 
vs PBS: 0.04  ±  0.01; p  >  0.05, Mann–Whitney U test, 
Fig.  3c) or complete transection (A91: 0.04  ±  0.02 vs 
PBS:0.06 ± 0.01 p > 0.05, Mann–Whitney U test; Fig. 3d). 
In the case of NT3, the results were quite similar. A sig-
nificant increase was observed in A91-immunized rats 
that were subjected to moderate contusion (0.09 ± 0.01, 
Fig. 4a) or hemisection (0.11 ± 0.01, Fig. 4b) in compari-
son to those immunized only with PBS (0.05 ± 0.02 and 
0.04 ± 0.01 moderate contusion and hemisection respec-
tively, p = 0.005, Mann–Whitney U test). A91-immuni-
zation did not induce any significant increase in NT-3 
levels when rats were subjected either to severe con-
tusion (Fig.  4c, A91: 0.04  ±  0.01 vs PBS: 0.05  ±  0.02.; 
p > 0.05, Mann–Whitney U test) or complete transection 
(Fig. 4d, A91: 0.05 ±  0.02 vs PBS 0.05 ±  0.01; p > 0.05, 
Fig. 1 A91‑immunization increases the levels of BDNF and NT‑3 at the site of injury. Twenty‑one days after injury the levels of this molecules were 
significantly higher in A91‑immunized rats than those observed in PBS‑immunized ones. Bars represent the mean ± SD of 5 rats. This is one repre‑
sentative of 3 experiments. *Different from PBS, p = 0.002; Mann–Whitney U test; **Different from PBS, p = 0.03, Mann–Whitney U test
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Mann–Whitney U test). In this rats NT-3 concentrations 
were also barely detected.
A91‑immunization maintained and improved motor 
performance in chronic stages of injury
In order to explore if the microenvironment induced by 
A91-immunization improves locomotor performance 
at chronic stage of SC-injury, we assessed motor func-
tion in rats with moderate contusion treated with either 
A91 (n = 10) or PBS (n = 10) immunization immediately 
after SC-injury. Evaluations were performed each week 
up to 4 months after injury using the BBB scale. Figure 5 
shows that A91-immunized rats presented higher BBB 
scores than those immunized only with PBS. From the 
beginning (1  week after SC-injury), A91-immuniza-
tion induced a significant increase in motor recovery 
(6.3  ±  0.2; mean  ±  SD) compared with PBS-treatment 
(2.4 ± 0.3). Two months after injury, A91-immunized rats 
continued showing a better BBB score (10.8 ± 0.2) when 
compared to PBS-treated ones (8.1  ±  0.3). At the end 
Fig. 2 Immunization with A91‑peptide elicits an immune response 
that is detected up to 4 months after SC injury. Anti‑A91 response 
was significantly higher in rats immunized with A91 relative to 
those immunized only with PBS. Bars represent the mean ± SD of 
5 rats. This is one representative of 3 experiments. *Different from 
PBS‑immunized rats, p = 0.001, Student t test. OVA ovalbumin, ConA 
concanavalin A
Fig. 3 BDNF concentrations 4 months after SC injury. The levels of BDNF in A91‑immunized rats were significantly higher only in rats with moderate 
contusion (a) or hemisection (b). In rats with severe contusion (c) or complete transection (d) A91‑immunization did not increase BDNF levels. Bars 
represent the mean ± SD of 5 rats. This is one representative of 3 experiments. *Different from PBS, p = 0.004; Mann–Whitney U test; **Different 
from PBS, p = 0.005, Mann–Whitney U test
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of the study, A91-immunization promoted an even bet-
ter motor performance (11.4 ± 0.3) compared to the one 
observed for the same group 2 months before (p = 0.02 
Wilcoxon signed rank test). In contrast, animals immu-
nized with PBS, showed a significant decline in the BBB 
score (7.0  ±  0.4) when compared to the one observed 
2 months before (p = 0.03 Wilcoxon signed rank test).
Discussion
Protective autoimmunity (PA) is a physiological and 
neuroprotective immune response mediated by T cells 
[4]. This innovative approach is in fact a T-cell-depend-
ent reaction that is genetically determined since only in 
animals of EAE-resistant strains (but not of suscepti-
ble strains), the injury evokes an endogenous protective 
response [13]. According to previous studies, genetic dif-
ferences originate a more intense inflammatory response 
in susceptible strains; a response that in nature, is detri-
mental instead of beneficial. Several studies have shown 
that PA is activated by the interaction of T cells with 
neural constituents present at the site of lesion after SC-
injury [3, 14, 15]. T cells interact with macrophages and 
resident microglia in an attempt to induce a protective 
response [3, 15]; however, the non-permissive microen-
vironment developed after injury leads to its failure and 
Fig. 4 NT3 levels 4 months after SC injury. NT3 concentrations were increased only in rats with moderate contusion (a) or hemisection (b). 
A91‑immunization failed to increase the levels of NT3 in severely contused (c) and transected (d) rats. Bars represent the mean ± SD of 5 rats. This is 
one representative of 3 experiments. *Different from PBS, p = 0.008; Mann–Whitney U test; **Different from PBS, p = 0.005, Mann–Whitney U test
Fig. 5 Motor recovery of rats with moderate SC‑contusion. Animals 
were treated either with A91 or PBS. A91‑immunization improved 
motor performance. *Different from PBS group (p = 0.01, two‑way 
ANOVA for repeated measures). Each point represents the mean ± SD 
of 10 rats
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PA is not sufficiently capable of protecting SC tissue [15, 
16]. Therefore, strategies to improve the effect of PA have 
been addressed.
A way of enhancing PA is through active immuniza-
tion with neural-derived peptides such as A91. Neural-
derived peptides interact with the T cell receptor (TCR) 
in a manner that modulates cytokine production [17, 18]. 
Additionally, these peptides promote T cell differentia-
tion into a Th2 phenotype capable of secreting IL-4 and 
IL-10 [9], cytokines that down-regulate the expression 
of NO [19]. Moreover, A91 induced PA has the ability 
to ameliorate neurotoxicity mainly through lipid peroxi-
dation inhibition [7], decrease in glutamate toxicity [20, 
21], reduction of apoptosis triggered by SC-injury [22] 
and amelioration of other neurotoxic processes [6, 23]. 
Collectively, these findings provide evidence to support 
the contention that PA is more a beneficial phenomenon 
than a detrimental one; however; there is still controversy 
about the idea of recognizing an autoreactive response as 
a protective or restorative phenomenon. In this respect, 
previous studies have shown that neural-reactive T cells 
of patients with SC-injury are in fact, similar to those 
found in patients with Multiple Sclerosis (MS). In both 
cases, T cells recognize the same antigenic regions [24]. 
Nevertheless, the difference in the cytokine produc-
tion between the two reactive T cells suggests that those 
derived from MS patients have a much higher inflamma-
tory potential.
In light of this scenario we could hypothesize that auto-
reactive responses could behave either as a harmful or a 
beneficial phenomenon. Autoreactivity is influenced by 
several factors (e.g. genetic predisposition) that could 
induce the development of an uncontrolled immune 
response that attacks the CNS. This is what we observe in 
MS. On the other hand, the modulation of autoreactive 
responses has shown to improve neurological function 
in MS and other neurodegenerative diseases [8, 24, 25]. 
Accordingly, if the reaction is immediately modulated (by 
immunizing with neural-derived antigens), the autoreac-
tive response is capable of providing beneficial effects.
Results from previous studies conducted in our labo-
ratory have shown that immunization with A91 confers 
a significant improvement in motor function compared 
to controls after SC-injury. Regarding the mechanisms 
underlying PA, we demonstrated that A91 immunization 
induces a specific anti-A91 response that is capable of 
producing—in vitro—brain derived neurotrophic factor 
(BDNF), a molecule that induces axonal regeneration and 
confers motor function improvement after SC-injury. 
Some studies have also shown that BDNF and another 
neurotrophic factor, NT-3, prevent neuronal apoptosis 
[26, 27] and promote axonal sprouting and regeneration 
[28–30].
In the present study we demonstrate that BDNF and 
NT-3 production is increased at the site of injury after 
active immunization with A91. Moreover, 4 months after 
injury, immunized rats presented a significant response 
against A91-peptide and a concomitant production of 
BDNF and NT-3. These observations shed light onto 
beneficial effects of PA, even at chronic stages.
Previous studies have already reported the presence of 
immune cells at chronic phases of injury. For instance, 
Guizar-Sahagún et  al. [31] reported the chronic pres-
ence of inflammatory cells (especially macrophages and 
lymphocytes) at the lesion site and nearby areas, even 
as late as 364  days post-injury. In the same way, Beck 
and colleagues reported cellular inflammation up to 
180 days after SC-injury [32]. In their investigation they 
also showed that the presence of immune cells at this 
stage has a reparative function since it avoids neurologi-
cal impairment. In the light of this finding, the presence 
of autoreactive responses against neural constituents 
in the late stages of SC-injury or traumatic brain injury 
(TBI) has also been documented and correlated with 
beneficial consequences [12, 33]. In the present work 
we showed that, even 4  months after A91 immuniza-
tion, proliferation of anti-A91 T cells is still present. The 
mechanisms that underlie the presence of this response 
at chronic stages should be the aim of further investiga-
tions. Nevertheless, we can hypothesize that its presence 
is the result of two possible events: (1) anti-A91 T cells 
are locally cross-reacting with MBP [34], a molecule that 
could be presented by antigen presenting cells (APC) at 
the lesion site; and (2) once activated, T lymphocytes dif-
ferentiate into memory cells that survive for a long time 
[35]. Therefore, immunization with A91-peptide could 
generate memory anti-A91 T cells that, along with APC 
in the site of injury, could be perpetuating the anti-A91 
response. These issues should be further analyzed.
The results of the present work support A91 immuni-
zation as a plausible agent to be administered soon after 
SC-injury in order to promote beneficial mechanisms 
that can improve functional recovery even at chronic 
phases of injury. It is important to emphasize the fact 
that a single A91 administration could provide patients 
with a long-term neurotrophic factor source, providing 
concomitant therapies (such as physical rehabilitation) a 
propitious microenvironment for further motor recovery. 
The presence of neurotrophic factors in chronic stages of 
injury opens the possibility for restorative phenomena 
like neurogenesis, axonal sprouting and other reparative 
mechanisms, to maintain or even improve the motor per-
formance observed in individuals with CNS injury [12, 
33]. In line with this, our results show that rats receiving 
A91 immunization presented an improved motor per-
formance that was maintained over time as compared to 
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those treated with PBS only. This is an important finding 
that merits further investigation.
Finally, another topic to be addressed from this work 
is the absence of BDNF and NT-3 molecules after severe 
injuries. Previous investigations from our laboratory had 
shown that PA is not present after severe SCI [9]. In the 
present study, we investigated if BDNF and NT-3 are 
present at the site of injury in different SC-injury mod-
els. Our results show that PA and neurotrophic factor 
production after immunization with A91 is only present 
after moderate SCC and hemisection and that BDNF and 
NT-3 concentrations were barely present after severe 
SCC and complete transection. After SC-injury, a cas-
cade of events that begin with the production of an auto-
nomic discharge is unleashed. As a response to trauma, 
there is secretion of stress molecules, such as catechola-
mines and cortisol. Leukocytes have glucocorticoid and 
catecholamine receptors, and this hormone-cell inter-
actions contribute to a state of immunodepression [36]. 
Additionally, prolonged exposure to catecholamines 
reduces the number of circulating T cells [37], produc-
ing an immunodeficiency called “SCI-induced immuno-
depression”. It is possible that this immunodepression 
limits the T cell capacity of processing and reacting 
towards a neural derived antigen, e.g. A91, thus prevent-
ing PA from occurring after immunization. Although the 
hypothesis of SCI-induced immunodepression impeding 
PA is plausible, the exact mechanisms and characteris-
tics of SC-injury that are responsible for inhibiting the 
action of PA are still in need of further investigation.
Conclusions
Immunization with A91 produces a chronic A91-reactive 
T cell response capable of promoting BDNF and NT-3 
production during the chronic stages of SC-injury. Also, 
we observed that A91-immunized rats had an improved 
locomotor recovery that was maintained up to 4 months 
after the lesion. It is very likely that this improvement is 
the result of an enhanced microenvironment rich in neu-
rotrophic factors induced by INDP.
The results from the present study bring hope to the 
clinical application of A91 as an immunomodulating 
therapeutic strategy. In the clinical prospect, nowadays 
there is no effective treatment after SC-injury. The only 
therapy that has been approved for human use is methyl-
prednisolone, which has not shown consistent results on 
its efficacy in the long run [38].
A source of both BDNF and NT-3, such as PA boosted 
by A91, could confer benefits to patients suffering from 
SC-injury and increase their chances of functional recov-
ery as well as offer an improvement in quality of life for 
them and their families.
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